Silexion Therapeutics Ltd.
SLXN$1.03
$-0.47 (-31.00%)-31.00%
ClosedLoading chart...
IndexN/A
Market Cap0.00B
Enterprise Value-0.00B
Income$-0.00B
Sales$0.00B
EmployeesN/A
P/E-0.03
P/S0.00
P/B0.98
P/C-0.24
EV/EBITDA0.25
EV/SalesN/A
EPS (ttm)-39.55
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume0.81M
Shs Outstand0.00B
Change-31.00%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Expenses | $12.57M | $4.68M | $3.86M | $943.93K | $195.86K |
| Operating Income | $-12.57M | $-4.68M | $-3.86M | $-943.93K | $-195.86K |
| Operating Margin | N/A | N/A | N/A | N/A | N/A |
| Net Income | $-16.44M | $-4.94M | $-3.21M | $-755.22K | $-195.86K |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS (Basic) | $-2.64 | $-4.42 | $0.03 | $-0.05 | $-0.01 |
| EBITDA | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $2.86M | $5.26M | $9.33M | $115.41M | $129.40K |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $6.85M | $17.31M | $16.41M | $508.92K | $299.39K |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $-3.99M | $-15.48M | $-10.66M | $114.91M | $-169.99K |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $-3.99M | $-15.48M | $-10.66M | $114.91M | $-169.99K |
| Total Liabilities & Stockholders Equity | $2.86M | $5.26M | $9.33M | $115.41M | $129.40K |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Income | $-16.44M | $-4.94M | $-3.21M | $-755.22K | $-195.86K |
| Depreciation | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-8.40M | $-4.53M | $-3.33M | $-1.41M | $-75.00K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offeringglobenewswire.com Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancersglobenewswire.com Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Centerglobenewswire.com Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancerglobenewswire.com Silexion Therapeutics to Attend BIO International Convention 2026globenewswire.com Silexion Therapeutics Announces 1-for-10 Reverse Share Splitglobenewswire.com Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceedsglobenewswire.com
Show 12 more stories
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancerglobenewswire.com Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Centerglobenewswire.com Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Centerglobenewswire.com Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancerglobenewswire.com Silexion Therapeutics (NASDAQ:SLXN) Shares Down 0.9% – Should You Sell?defenseworld.net Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancerglobenewswire.com Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancerglobenewswire.com Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updateglobenewswire.com Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancerglobenewswire.com Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conferenceglobenewswire.com Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancerglobenewswire.com Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updateglobenewswire.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Discover more
You may be interested in